Philip AshtonRickardt - Sigilon Therapeutics Chief Officer
Insider
Philip AshtonRickardt is Chief Officer of Sigilon Therapeutics
| Age | 59 |
| Phone | 617 336 7540 |
| Web | https://www.sigilon.com |
Philip AshtonRickardt Latest Insider Activity
Tracking and analyzing the buying and selling activities of Philip AshtonRickardt against Sigilon Therapeutics stock is an integral part of due diligence when investing in Sigilon Therapeutics. Philip AshtonRickardt insider activity provides valuable insight into whether Sigilon Therapeutics is net buyers or sellers over its current business cycle. Note, Sigilon Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Sigilon Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Philip AshtonRickardt over a year ago Acquisition by Philip AshtonRickardt of 115000 shares of Sigilon TherapeuticsInc subject to Rule 16b-3 |
Sigilon Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2365) % which means that it has lost $0.2365 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7631) %, meaning that it created substantial loss on money invested by shareholders. Sigilon Therapeutics' management efficiency ratios could be used to measure how well Sigilon Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Sigilon Therapeutics currently holds 28.06 M in liabilities with Debt to Equity (D/E) ratio of 0.61, which is about average as compared to similar companies. Sigilon Therapeutics has a current ratio of 2.71, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Sigilon Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Swan Sit | NovaBay Pharmaceuticals | 41 | |
| Michael PEng | InMed Pharmaceuticals | 56 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 70 | |
| Keith MD | X4 Pharmaceuticals | 54 | |
| Karen Cashmere | ZyVersa Therapeutics | 73 | |
| Narayan Prabhu | Reviva Pharmaceuticals Holdings | 53 | |
| MBA JD | Cardio Diagnostics Holdings | 60 | |
| Jeffrey Welch | GeoVax Labs | N/A | |
| MD FACP | Sonnet Biotherapeutics Holdings | 67 | |
| Mark Newman | GeoVax Labs | 70 | |
| McKee MD | GeoVax Labs | 72 | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| Sazzad MSc | InMed Pharmaceuticals | 66 | |
| Jeffrey MD | NovaBay Pharmaceuticals | 61 | |
| MPA MD | Unicycive Therapeutics | 52 | |
| Ado Muhammad | InMed Pharmaceuticals | N/A | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Mary DiBiase | X4 Pharmaceuticals | 64 | |
| Dr MedSc | Phio Pharmaceuticals Corp | 68 | |
| Colin Clancy | InMed Pharmaceuticals | N/A | |
| CGA CPA | InMed Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.76 | |||
| Return On Asset | -0.24 |
Sigilon Therapeutics Leadership Team
Elected by the shareholders, the Sigilon Therapeutics' board of directors comprises two types of representatives: Sigilon Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sigilon. The board's role is to monitor Sigilon Therapeutics' management team and ensure that shareholders' interests are well served. Sigilon Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sigilon Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Philip AshtonRickardt, Chief Officer | ||
| MD MBA, Ex Officer | ||
| Arturo Vegas, CoFounder | ||
| Omid Veiseh, CoFounder | ||
| Daniel Anderson, CoFounder Board | ||
| MBA MD, CEO Pres | ||
| Jos MD, CoFounder | ||
| JD Windsor, VP Relations | ||
| Josias MBA, VP, CFO |
Sigilon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sigilon Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.76 | |||
| Return On Asset | -0.24 | |||
| Profit Margin | (1.71) % | |||
| Operating Margin | (1.75) % | |||
| Current Valuation | 28.99 M | |||
| Shares Outstanding | 2.5 M | |||
| Shares Owned By Insiders | 8.69 % | |||
| Shares Owned By Institutions | 54.33 % | |||
| Number Of Shares Shorted | 8.23 K | |||
| Price To Book | 0.25 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Sigilon Stock
If you are still planning to invest in Sigilon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sigilon Therapeutics' history and understand the potential risks before investing.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |